68Ga-P16-093 PET/CT Imaging in the Salivary Gland

Status Not yet recruiting

Clinical Trial Summary

Prostate specific membrane antigen (PSMA) is a type II transmembrane protein and acts as a glutamate carboxypeptidase enzyme. It is first described in prostate cancer cell lines and later identified in various tissues, include salivary gland. This pilot study was designed to evaluate the diagnostic performance of 68Ga-P16-093 in primary sjogren's syndrome patients.

Clinical Trial Description

Primary sjogren's syndrome (pSS) is a systemic autoimmune disease mainly presented hyperglobulinemia and exocrine gland involvement,and lack of diagnostic gold standard.Prostate-specific membrane antigen (PSMA), as known as folate hydrolase I or glutamate carboxypeptidase II, is overexpressed on the cells of prostatic adenocarcinoma. However, PSMA is also expressed by various solid organs , such as salivary gland,which is often observed damage in primary Sjogren's syndrome patients.Therefore, PSMA may be an ideal target for evaluating salivary gland injury. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06049368
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Zhaohui Zhu, MD
Phone	86-13611093752
Email	13611093752@163.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	October 1, 2023
Completion date	March 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06440525` - A Phase 2 Study of RSLV-132 in Females With Primary Sjögren's Syndrome	Phase 2
Not yet recruiting	`NCT03140111` - LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients	N/A
Not yet recruiting	`NCT03614299` - Eye Dryness Evaluation in Primary Sjögren's Syndrome
Not yet recruiting	`NCT03126383` - Inflammatory Myopathies in Primary Sjögren's Syndrome	N/A
Recruiting	`NCT04830644` - A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.	Phase 2
Not yet recruiting	`NCT03765593` - Biomarkers in Primary Sjögren's Syndrome
Completed	`NCT01081184` - Neurotrophins Implications in Primary Sjögren Syndrome	N/A
Completed	`NCT05670535` - Sjögren and Gynecologic Considerations
Completed	`NCT03226444` - Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome	Phase 1/Phase 2
Completed	`NCT04816370` - Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions	N/A
Completed	`NCT05380804` - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Terminated	`NCT04700280` - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)	Phase 2
Completed	`NCT03130062` - Resistance Exercise in Woman With Primary Sjörgen Syndrome.	N/A
Completed	`NCT04093531` - Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome	Phase 1
Recruiting	`NCT03509064` - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Completed	`NCT04224454` - Vaccine Coverage and Primary Sjögren'Syndrome
Completed	`NCT04960605` - Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome	N/A
Recruiting	`NCT06361745` - Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases	N/A